Interestingly, when TGFβ1 was blocked with a TGFβ1-neutralizing antibody, the cancer-killing efficiency of CD8+ T cells significantly increased, along with an increased proportion of IFN-γ+ and GZMB+ CD8+ T cells (Figures 5B-C). The gene discussed is GZMB; the disease is cancer.